These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 36195780

  • 1. Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma.
    Dinh CT, Vu HT, Phan QTH, Nguyen LP, Tran TQ, Van Tran D, Quy NN, Pham DTN, Nguyen DT.
    J Mater Sci Mater Med; 2022 Oct 04; 33(10):72. PubMed ID: 36195780
    [Abstract] [Full Text] [Related]

  • 2. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
    Sun Y, Dai C, Yin M, Lu J, Hu H, Chen D.
    Int J Nanomedicine; 2018 Oct 04; 13():1621-1632. PubMed ID: 29588589
    [Abstract] [Full Text] [Related]

  • 3. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery.
    He ZY, Zheng X, Wu XH, Song XR, He G, Wu WF, Yu S, Mao SJ, Wei YQ.
    Int J Pharm; 2010 Sep 15; 397(1-2):147-54. PubMed ID: 20667672
    [Abstract] [Full Text] [Related]

  • 4. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M, Wang J, Bai J, Li X, Tian C, Liu Z, Zheng C, Clark AR, Cheng X, Liao X, Wu S, Lee RJ, Zhou X.
    Mol Pharm; 2023 Apr 03; 20(4):1951-1963. PubMed ID: 36952242
    [Abstract] [Full Text] [Related]

  • 5. Construction of redox-sensitive liposomes modified by glycyrrhetinic acid and evaluation of anti-hepatocellular carcinoma activity.
    Hu J, Zheng Y, Wen Z, Fu H, Yang X, Ye X, Zhu S, Kang L, Li X, Yang X, Hu Y.
    Chem Phys Lipids; 2023 May 03; 252():105292. PubMed ID: 36931583
    [Abstract] [Full Text] [Related]

  • 6. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
    Chen F, Zhang J, He Y, Fang X, Wang Y, Chen M.
    Biomater Sci; 2016 Jan 03; 4(1):167-82. PubMed ID: 26484363
    [Abstract] [Full Text] [Related]

  • 7. Glycyrrhetinic Acid Liposomes Containing Mannose-Diester Lauric Diacid-Cholesterol Conjugate Synthesized by Lipase-Catalytic Acylation for Liver-Specific Delivery.
    Chen J, Chen Y, Cheng Y, Gao Y.
    Molecules; 2017 Sep 24; 22(10):. PubMed ID: 28946644
    [Abstract] [Full Text] [Related]

  • 8. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
    Zhao L, Liang L, Guo M, Li M, Yu X, Wang Y, Wang Y.
    Curr Top Med Chem; 2021 Oct 05; 21(14):1268-1284. PubMed ID: 34620053
    [Abstract] [Full Text] [Related]

  • 9. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
    Huang S, Ren D, Wu X, Li M, Yu X, Nie X, Wang Y, Wang Y.
    Curr Top Med Chem; 2020 Oct 05; 20(27):2493-2505. PubMed ID: 32703132
    [Abstract] [Full Text] [Related]

  • 10. A low-cost, flexible extruder for liposomes synthesis and application for Murrayafoline A delivery for cancer treatment.
    Pham DT, Nguyen LP, Pham QTH, Pham CK, Pham DTN, Viet NT, Nguyen HVT, Tran TQ, Nguyen DT.
    J Biomater Appl; 2022 Nov 05; 37(5):872-880. PubMed ID: 35786069
    [Abstract] [Full Text] [Related]

  • 11. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects.
    Tian J, Wang L, Wang L, Ke X.
    Drug Deliv; 2014 Nov 05; 21(7):553-9. PubMed ID: 24215357
    [Abstract] [Full Text] [Related]

  • 12. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
    Li J, Xu H, Ke X, Tian J.
    J Drug Target; 2012 Jun 05; 20(5):467-73. PubMed ID: 22577855
    [Abstract] [Full Text] [Related]

  • 13. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
    Wu F, Xue H, Li X, Diao W, Jiang B, Wang W, Yu W, Bai J, Wang Y, Lian B, Feng W, Sun T, Qu M, Zhao C, Wang Y, Wu J, Gao Z.
    Biomed Pharmacother; 2020 Nov 05; 131():110682. PubMed ID: 32947204
    [Abstract] [Full Text] [Related]

  • 14. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
    Pathak P, Dhawan V, Magarkar A, Danne R, Govindarajan S, Ghosh S, Steiniger F, Chaudhari P, Gopal V, Bunker A, Róg T, Fahr A, Nagarsenker M.
    Int J Pharm; 2016 Jul 25; 509(1-2):149-158. PubMed ID: 27231122
    [Abstract] [Full Text] [Related]

  • 15. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells.
    Sun Y, Lu J, Yan D, Shen L, Hu H, Chen D.
    Environ Toxicol Pharmacol; 2017 Jul 25; 53():46-56. PubMed ID: 28501784
    [Abstract] [Full Text] [Related]

  • 16. Use of different ligand modification liposomes to evaluate the anti-liver tumor activity of cantharidin.
    Zou M, Xu Y, Lin P, Zhou L, Xia X.
    J Liposome Res; 2023 Sep 25; 33(3):283-299. PubMed ID: 36594207
    [Abstract] [Full Text] [Related]

  • 17. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma.
    Li X, Diao W, Xue H, Wu F, Wang W, Jiang B, Bai J, Lian B, Feng W, Sun T, Yu W, Wu J, Qu M, Wang Y, Gao Z.
    Cancer Lett; 2020 Oct 01; 489():163-173. PubMed ID: 32592729
    [Abstract] [Full Text] [Related]

  • 18. Preparation and pharmacokinetics of glycyrrhetinic acid and cell transmembrane peptides modified with liposomes for liver targeted-delivery.
    Li L, Chen A, Liu B, Pan H, Yu Y, Liu Y.
    Biomed Mater; 2022 May 13; 17(4):. PubMed ID: 35483344
    [Abstract] [Full Text] [Related]

  • 19. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
    Zhang J, Zhang M, Ji J, Fang X, Pan X, Wang Y, Wu C, Chen M.
    Pharm Res; 2015 Oct 13; 32(10):3376-90. PubMed ID: 26148773
    [Abstract] [Full Text] [Related]

  • 20. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
    Yang T, Lan Y, Cao M, Ma X, Cao A, Sun Y, Yang J, Li L, Liu Y.
    Colloids Surf B Biointerfaces; 2019 Mar 01; 175():106-115. PubMed ID: 30529816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.